影像引导下宫腔管与圆柱形施源器近距离放疗作为不可手术子宫内膜癌的根治性单一治疗
本系列回顾了45例 grade 1-2、临床I期、肌层浸润<50%、肿瘤≤2cm的子宫内膜腺癌患者,接受单纯HDR-IGBT(5-6次,CT或MRI计划)。中位剂量37.5Gy,2年局部区域控制率90%、癌特异生存率86%、总生存率97%,无3级以上急性或晚期毒性。
要点
- 单纯HDR-IGBT对早期、医学上不可手术的子宫内膜癌可行,应答率和临床结果良好。
- 98%患者阴道出血停止,64%有治疗后MRI者中90%显示完全影像学应答。
- 2年局部区域控制率90%、癌特异生存率86%、总生存率97%,无3级以上毒性。
核心结论
- 单纯HDR-IGBT治疗早期、医学上不可手术的子宫内膜癌可行,应答率和临床结果良好,与2D点式系列相比毒性低且局部区域控制率高,并允许保护关键器官和确保靶区覆盖。
研究设计与样本
- 回顾性系列,纳入2007年至2016年接受单纯HDR-IGBT根治性治疗的45例grade 1-2、临床I期子宫内膜腺癌患者,肿瘤≤2cm且肌层浸润<50%,治疗为5-6次HDR-IGBT,基于CT或MRI计划。
主要发现
- 中位剂量37.5Gy,中位GTV为5.9cm3(范围0.7-18.7),中位CTV为80.9cm3(范围17.2-159.0)。
- GTV D90中位累积剂量为132.8Gy(范围76.5-295.6)等效2Gy剂量,CTV D90中位为49.7Gy(范围34.5-57.2)。
- 98%患者阴道出血停止;64%有治疗后MRI者中90%显示完全影像学应答。
- 2年局部区域控制率90%、癌特异生存率86%、总生存率97%。
- 未观察到3级以上急性或晚期毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Management of endometrial cancer consists of surgical staging with adjuvant therapy guided by risk factors, though some women cannot undergo surgery due to comorbidities. We present a series of women treated with definitive high-dose rate image-guided tandem and cylinder brachytherapy (HDR-IGBT) alone. METHODS: Patients with grade 1-2, clinical stage I endometrial adenocarcinoma, <50% myometrial invasion, and tumor≤2cm were reviewed. Definitive treatment consisted of 5-6 fractions HDR-IGBT alone with CT- or MRI-based planning. Local-regional control (LRC) was defined as complete imaging response and/or cessation of vaginal bleeding. RESULTS: From 2007 to 2016, 45 patients were treated to a median dose of 37.5Gy. The median gross tumor volume (GTV) and clinical target volume (CTV) were 5.9cm3 (range, 0.7-18.7) and 80.9cm3 (17.2-159.0), respectively. The median cumulative dose to 90% (D90) of the GTV was 132.8Gy (76.5-295.6) equivalent 2Gy dose, and the median CTV D90 was 49.7Gy (34.5-57.2). Median follow-up among living patients was 18.6months (3.0-64.3). Cessation of vaginal bleeding occurred in 98%. Among those with post-treatment MRI (64%), complete radiographic response was demonstrated in 90%. The 2-year LRC, cancer-specific survival, and overall survival rates were 90%, 86%, and 97%, respectively. No grade 3+ acute or late toxicity was observed. CONCLUSIONS: HDR-IGBT alone for treatment of early-stage, medically inoperable endometrial cancer is feasible with excellent response rates and clinical results. This approach also allows sparing of critical organs and ensures target coverage, which contributed to the low toxicity rate and high LRC in comparison with 2D point-based series.
引用
- Gebhardt B, Gill B, Glaser S, et al. Image-guided tandem and cylinder brachytherapy as monotherapy for definitive treatment of inoperable endometrial carcinoma. Gynecol Oncol. 2017. PMID: 28923412. doi:10.1016/j.ygyno.2017.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。